Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306384 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,323
- Enrollment target
NCT00306384 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 3,323 participants.
The verdict
NCT00306384, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,323 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
Interventions
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,323 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306384
The ClinicalTrials.gov registry entry for NCT00306384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alogliptin is the first listed.
NCT00306384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306384 about?
NCT00306384 is a clinical study titled "Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
What is the current status of trial NCT00306384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,323 participants. The study started on 2006-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00306384?
The interventions under investigation include: Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00306384?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.